http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 16 Jun 2026 08:10:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cingulate+Inc.++++++++++++For%3A+Jun+16/26650871.html si-local-file:///var/storage/secattach/20260616/26650871.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cingulate+Inc.++++++++++++For%3A+Jun+16/26650871.html Tue, 16 Jun 2026 08:10:00 -0400 CING O.52480795 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cingulate+Inc.++++++++++++For%3A+Jun+16/26650871.html si-local-file:///var/storage/secattach/20260616/26650871.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cingulate+Inc.++++++++++++For%3A+Jun+16/26650871.html Tue, 16 Jun 2026 08:10:00 -0400 CING O.52480795 http://www.streetinsider.com/Corporate+News/Cingulate+receives+first+U.S.+patent+for+ADHD+drug+candidate+CTx-1301/26650757.html <p>Cingulate Inc. (NASDAQ: CING) announced that the United States Patent and Trademark Office issued the company its first wholly owned U.S. patent covering its lead drug candidate, CTx-1301 (dexmethylphenidate HCl), an ADHD treatment in development.</p><p>The patent, U.S. Patent No. 12,653,791, was issued June 16, 2026, and provides protection through December 2042. Titled "Trimodal, Precision-Timed Pulsatile Release Tablet," it covers composition-of-matter, formulation, structural, and method-of-treatment claims related to CTx-1301's tablet technology, which is designed to release medication in three distinct phases from a single daily dose.</p><p>Cingulate CEO Shane J. Schaffer said in a statement: "This patent represents another important milestone in http://www.streetinsider.com/Corporate+News/Cingulate+receives+first+U.S.+patent+for+ADHD+drug+candidate+CTx-1301/26650757.html Tue, 16 Jun 2026 08:02:00 -0400 CING CINGW http://www.streetinsider.com/Corporate+News/Cingulate+receives+first+U.S.+patent+for+ADHD+drug+candidate+CTx-1301/26650757.html <p>Cingulate Inc. (NASDAQ: CING) announced that the United States Patent and Trademark Office issued the company its first wholly owned U.S. patent covering its lead drug candidate, CTx-1301 (dexmethylphenidate HCl), an ADHD treatment in development.</p><p>The patent, U.S. Patent No. 12,653,791, was issued June 16, 2026, and provides protection through December 2042. Titled "Trimodal, Precision-Timed Pulsatile Release Tablet," it covers composition-of-matter, formulation, structural, and method-of-treatment claims related to CTx-1301's tablet technology, which is designed to release medication in three distinct phases from a single daily dose.</p><p>Cingulate CEO Shane J. Schaffer said in a statement: "This patent represents another important milestone in http://www.streetinsider.com/Corporate+News/Cingulate+receives+first+U.S.+patent+for+ADHD+drug+candidate+CTx-1301/26650757.html Tue, 16 Jun 2026 08:02:00 -0400 CING CINGW http://www.streetinsider.com/Press+Releases/Cingulate+Issued+First+U.S.+Patent+for+Lead+ADHD+Asset+CTx-1301/26650745.html <p>KANSAS CITY, Kan., June 16, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the issuance of its first company-owned U.S. patent covering its lead asset, CTx-1301 (dexmethylphenidate HCl), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).</p> <p>The patent, issued by the United States Patent and Trademark Office (USPTO) on June 16, 2026, as U.S. Patent No. 12,653,791, protects key aspects of CTx-1301’s formulation and method of use through December 2042, http://www.streetinsider.com/Press+Releases/Cingulate+Issued+First+U.S.+Patent+for+Lead+ADHD+Asset+CTx-1301/26650745.html Tue, 16 Jun 2026 08:00:00 -0400 A.14320728 A.23650007 CING CINGW O.20250741 O.41161166 O.52480795 http://www.streetinsider.com/Press+Releases/Cingulate+Issued+First+U.S.+Patent+for+Lead+ADHD+Asset+CTx-1301/26650745.html <p>KANSAS CITY, Kan., June 16, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the issuance of its first company-owned U.S. patent covering its lead asset, CTx-1301 (dexmethylphenidate HCl), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).</p> <p>The patent, issued by the United States Patent and Trademark Office (USPTO) on June 16, 2026, as U.S. Patent No. 12,653,791, protects key aspects of CTx-1301’s formulation and method of use through December 2042, http://www.streetinsider.com/Press+Releases/Cingulate+Issued+First+U.S.+Patent+for+Lead+ADHD+Asset+CTx-1301/26650745.html Tue, 16 Jun 2026 08:00:00 -0400 A.14320728 A.23650007 CING CINGW O.20250741 O.41161166 O.52480795 http://www.streetinsider.com/Press+Releases/Cingulate+Issued+First+U.S.+Patent+for+Lead+ADHD+Asset+CTx-1301/26650745.html <p>KANSAS CITY, Kan., June 16, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the issuance of its first company-owned U.S. patent covering its lead asset, CTx-1301 (dexmethylphenidate HCl), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).</p> <p>The patent, issued by the United States Patent and Trademark Office (USPTO) on June 16, 2026, as U.S. Patent No. 12,653,791, protects key aspects of CTx-1301’s formulation and method of use through December 2042, http://www.streetinsider.com/Press+Releases/Cingulate+Issued+First+U.S.+Patent+for+Lead+ADHD+Asset+CTx-1301/26650745.html Tue, 16 Jun 2026 08:00:00 -0400 A.14320728 A.23650007 CING CINGW O.20250741 O.41161166 O.52480795 http://www.streetinsider.com/Press+Releases/Cingulate+Issued+First+U.S.+Patent+for+Lead+ADHD+Asset+CTx-1301/26650745.html <p>KANSAS CITY, Kan., June 16, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the issuance of its first company-owned U.S. patent covering its lead asset, CTx-1301 (dexmethylphenidate HCl), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).</p> <p>The patent, issued by the United States Patent and Trademark Office (USPTO) on June 16, 2026, as U.S. Patent No. 12,653,791, protects key aspects of CTx-1301’s formulation and method of use through December 2042, http://www.streetinsider.com/Press+Releases/Cingulate+Issued+First+U.S.+Patent+for+Lead+ADHD+Asset+CTx-1301/26650745.html Tue, 16 Jun 2026 08:00:00 -0400 A.14320728 A.23650007 CING CINGW O.20250741 O.41161166 O.52480795 http://www.streetinsider.com/Press+Releases/Cingulate+Issued+First+U.S.+Patent+for+Lead+ADHD+Asset+CTx-1301/26650745.html <p>KANSAS CITY, Kan., June 16, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the issuance of its first company-owned U.S. patent covering its lead asset, CTx-1301 (dexmethylphenidate HCl), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).</p> <p>The patent, issued by the United States Patent and Trademark Office (USPTO) on June 16, 2026, as U.S. Patent No. 12,653,791, protects key aspects of CTx-1301’s formulation and method of use through December 2042, http://www.streetinsider.com/Press+Releases/Cingulate+Issued+First+U.S.+Patent+for+Lead+ADHD+Asset+CTx-1301/26650745.html Tue, 16 Jun 2026 08:00:00 -0400 A.14320728 A.23650007 CING CINGW O.20250741 O.41161166 O.52480795 http://www.streetinsider.com/Press+Releases/Cingulate+Issued+First+U.S.+Patent+for+Lead+ADHD+Asset+CTx-1301/26650745.html <p>KANSAS CITY, Kan., June 16, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the issuance of its first company-owned U.S. patent covering its lead asset, CTx-1301 (dexmethylphenidate HCl), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).</p> <p>The patent, issued by the United States Patent and Trademark Office (USPTO) on June 16, 2026, as U.S. Patent No. 12,653,791, protects key aspects of CTx-1301’s formulation and method of use through December 2042, http://www.streetinsider.com/Press+Releases/Cingulate+Issued+First+U.S.+Patent+for+Lead+ADHD+Asset+CTx-1301/26650745.html Tue, 16 Jun 2026 08:00:00 -0400 A.14320728 A.23650007 CING CINGW O.20250741 O.41161166 O.52480795 http://www.streetinsider.com/Press+Releases/Cingulate+Issued+First+U.S.+Patent+for+Lead+ADHD+Asset+CTx-1301/26650745.html <p>KANSAS CITY, Kan., June 16, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the issuance of its first company-owned U.S. patent covering its lead asset, CTx-1301 (dexmethylphenidate HCl), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).</p> <p>The patent, issued by the United States Patent and Trademark Office (USPTO) on June 16, 2026, as U.S. Patent No. 12,653,791, protects key aspects of CTx-1301’s formulation and method of use through December 2042, http://www.streetinsider.com/Press+Releases/Cingulate+Issued+First+U.S.+Patent+for+Lead+ADHD+Asset+CTx-1301/26650745.html Tue, 16 Jun 2026 08:00:00 -0400 A.14320728 A.23650007 CING CINGW O.20250741 O.41161166 O.52480795 http://www.streetinsider.com/Globe+Newswire/Cingulate+Issued+First+U.S.+Patent+for+Lead+ADHD+Asset+CTx-1301/26650745.html <p>KANSAS CITY, Kan., June 16, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the issuance of its first company-owned U.S. patent covering its lead asset, CTx-1301 (dexmethylphenidate HCl), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).</p> <p>The patent, issued by the United States Patent and Trademark Office (USPTO) on June 16, 2026, as U.S. Patent No. 12,653,791, protects key aspects of CTx-1301’s formulation and method of use through December 2042, http://www.streetinsider.com/Globe+Newswire/Cingulate+Issued+First+U.S.+Patent+for+Lead+ADHD+Asset+CTx-1301/26650745.html Tue, 16 Jun 2026 08:00:00 -0400 A.14320728 A.23650007 CING CINGW O.20250741 O.41161166 O.52480795 http://www.streetinsider.com/Globe+Newswire/Cingulate+Issued+First+U.S.+Patent+for+Lead+ADHD+Asset+CTx-1301/26650745.html <p>KANSAS CITY, Kan., June 16, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the issuance of its first company-owned U.S. patent covering its lead asset, CTx-1301 (dexmethylphenidate HCl), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).</p> <p>The patent, issued by the United States Patent and Trademark Office (USPTO) on June 16, 2026, as U.S. Patent No. 12,653,791, protects key aspects of CTx-1301’s formulation and method of use through December 2042, http://www.streetinsider.com/Globe+Newswire/Cingulate+Issued+First+U.S.+Patent+for+Lead+ADHD+Asset+CTx-1301/26650745.html Tue, 16 Jun 2026 08:00:00 -0400 A.14320728 A.23650007 CING CINGW O.20250741 O.41161166 O.52480795 http://www.streetinsider.com/Globe+Newswire/Cingulate+Issued+First+U.S.+Patent+for+Lead+ADHD+Asset+CTx-1301/26650745.html <p>KANSAS CITY, Kan., June 16, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the issuance of its first company-owned U.S. patent covering its lead asset, CTx-1301 (dexmethylphenidate HCl), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).</p> <p>The patent, issued by the United States Patent and Trademark Office (USPTO) on June 16, 2026, as U.S. Patent No. 12,653,791, protects key aspects of CTx-1301’s formulation and method of use through December 2042, http://www.streetinsider.com/Globe+Newswire/Cingulate+Issued+First+U.S.+Patent+for+Lead+ADHD+Asset+CTx-1301/26650745.html Tue, 16 Jun 2026 08:00:00 -0400 A.14320728 A.23650007 CING CINGW O.20250741 O.41161166 O.52480795 http://www.streetinsider.com/Globe+Newswire/Cingulate+Issued+First+U.S.+Patent+for+Lead+ADHD+Asset+CTx-1301/26650745.html <p>KANSAS CITY, Kan., June 16, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the issuance of its first company-owned U.S. patent covering its lead asset, CTx-1301 (dexmethylphenidate HCl), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).</p> <p>The patent, issued by the United States Patent and Trademark Office (USPTO) on June 16, 2026, as U.S. Patent No. 12,653,791, protects key aspects of CTx-1301’s formulation and method of use through December 2042, http://www.streetinsider.com/Globe+Newswire/Cingulate+Issued+First+U.S.+Patent+for+Lead+ADHD+Asset+CTx-1301/26650745.html Tue, 16 Jun 2026 08:00:00 -0400 A.14320728 A.23650007 CING CINGW O.20250741 O.41161166 O.52480795 http://www.streetinsider.com/Globe+Newswire/Cingulate+Issued+First+U.S.+Patent+for+Lead+ADHD+Asset+CTx-1301/26650745.html <p>KANSAS CITY, Kan., June 16, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the issuance of its first company-owned U.S. patent covering its lead asset, CTx-1301 (dexmethylphenidate HCl), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).</p> <p>The patent, issued by the United States Patent and Trademark Office (USPTO) on June 16, 2026, as U.S. Patent No. 12,653,791, protects key aspects of CTx-1301’s formulation and method of use through December 2042, http://www.streetinsider.com/Globe+Newswire/Cingulate+Issued+First+U.S.+Patent+for+Lead+ADHD+Asset+CTx-1301/26650745.html Tue, 16 Jun 2026 08:00:00 -0400 A.14320728 A.23650007 CING CINGW O.20250741 O.41161166 O.52480795 http://www.streetinsider.com/Globe+Newswire/Cingulate+Issued+First+U.S.+Patent+for+Lead+ADHD+Asset+CTx-1301/26650745.html <p>KANSAS CITY, Kan., June 16, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the issuance of its first company-owned U.S. patent covering its lead asset, CTx-1301 (dexmethylphenidate HCl), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).</p> <p>The patent, issued by the United States Patent and Trademark Office (USPTO) on June 16, 2026, as U.S. Patent No. 12,653,791, protects key aspects of CTx-1301’s formulation and method of use through December 2042, http://www.streetinsider.com/Globe+Newswire/Cingulate+Issued+First+U.S.+Patent+for+Lead+ADHD+Asset+CTx-1301/26650745.html Tue, 16 Jun 2026 08:00:00 -0400 A.14320728 A.23650007 CING CINGW O.20250741 O.41161166 O.52480795 http://www.streetinsider.com/Globe+Newswire/Cingulate+Issued+First+U.S.+Patent+for+Lead+ADHD+Asset+CTx-1301/26650745.html <p>KANSAS CITY, Kan., June 16, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the issuance of its first company-owned U.S. patent covering its lead asset, CTx-1301 (dexmethylphenidate HCl), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).</p> <p>The patent, issued by the United States Patent and Trademark Office (USPTO) on June 16, 2026, as U.S. Patent No. 12,653,791, protects key aspects of CTx-1301’s formulation and method of use through December 2042, http://www.streetinsider.com/Globe+Newswire/Cingulate+Issued+First+U.S.+Patent+for+Lead+ADHD+Asset+CTx-1301/26650745.html Tue, 16 Jun 2026 08:00:00 -0400 A.14320728 A.23650007 CING CINGW O.20250741 O.41161166 O.52480795 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cingulate+Inc.++++++++++++For%3A+Feb+13++Filed+by%3A+Hargroves+Thomas+Jeffrey/26618726.html si-local-file:///var/storage/secattach/20260608/26618726.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cingulate+Inc.++++++++++++For%3A+Feb+13++Filed+by%3A+Hargroves+Thomas+Jeffrey/26618726.html Mon, 08 Jun 2026 19:02:00 -0400 CING O.52480795 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cingulate+Inc.++++++++++++For%3A+Feb+13++Filed+by%3A+Hargroves+Thomas+Jeffrey/26618726.html si-local-file:///var/storage/secattach/20260608/26618726.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cingulate+Inc.++++++++++++For%3A+Feb+13++Filed+by%3A+Hargroves+Thomas+Jeffrey/26618726.html Mon, 08 Jun 2026 19:02:00 -0400 CING O.52480795 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Cingulate+Inc.++++++++++++For%3A+Feb+13++Filed+by%3A+Hargroves+Thomas+Jeffrey/26618717.html si-local-file:///var/storage/secattach/20260608/26618717.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Cingulate+Inc.++++++++++++For%3A+Feb+13++Filed+by%3A+Hargroves+Thomas+Jeffrey/26618717.html Mon, 08 Jun 2026 19:00:00 -0400 CING O.52480795 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Cingulate+Inc.++++++++++++For%3A+Feb+13++Filed+by%3A+Hargroves+Thomas+Jeffrey/26618717.html si-local-file:///var/storage/secattach/20260608/26618717.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Cingulate+Inc.++++++++++++For%3A+Feb+13++Filed+by%3A+Hargroves+Thomas+Jeffrey/26618717.html Mon, 08 Jun 2026 19:00:00 -0400 CING O.52480795 http://www.streetinsider.com/Press+Releases/Stonegate+Capital+Partners+Updates+Coverage+on+Cingulate+Inc.+%28CING%29+1Q26/26606487.html <p> Dallas, Texas--(Newsfile Corp. - June 4, 2026) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates coverage on Cingulate Inc. (NASDAQ: CING). Cingulate's latest update shifts the near-term CTx-1301 setup from a PDUFA driven approval event to a CMC-driven resubmission process, while leaving the core product thesis intact based on the information disclosed. The FDA issued a Complete Response Letter for the CTx-1301 NDA focused on specific CMC information requests, with no current clinical safety or efficacy concerns identified. In our view, the key http://www.streetinsider.com/Press+Releases/Stonegate+Capital+Partners+Updates+Coverage+on+Cingulate+Inc.+%28CING%29+1Q26/26606487.html Thu, 04 Jun 2026 16:48:00 -0400 CING http://www.streetinsider.com/Newsfile/Stonegate+Capital+Partners+Updates+Coverage+on+Cingulate+Inc.+%28CING%29+1Q26/26606487.html <p> Dallas, Texas--(Newsfile Corp. - June 4, 2026) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates coverage on Cingulate Inc. (NASDAQ: CING). Cingulate's latest update shifts the near-term CTx-1301 setup from a PDUFA driven approval event to a CMC-driven resubmission process, while leaving the core product thesis intact based on the information disclosed. The FDA issued a Complete Response Letter for the CTx-1301 NDA focused on specific CMC information requests, with no current clinical safety or efficacy concerns identified. In our view, the key http://www.streetinsider.com/Newsfile/Stonegate+Capital+Partners+Updates+Coverage+on+Cingulate+Inc.+%28CING%29+1Q26/26606487.html Thu, 04 Jun 2026 16:48:00 -0400 CING http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cingulate+Inc.++++++++++++For%3A+Jun+02/26587929.html si-local-file:///var/storage/secattach/20260602/26587929.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cingulate+Inc.++++++++++++For%3A+Jun+02/26587929.html Tue, 02 Jun 2026 08:10:00 -0400 CING O.52480795